Hans-Peter Torsten Ekre
Founder at NEXTCELL PHARMA AB
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Edvard Smith | M | 73 | 10 years | |
| Carl Harald Janson | M | 66 |
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna.
KCIF Fund Management AB
| 4 years |
| Jan Peter Olofsson | M | 52 |
ProNoxis AB
 ProNoxis AB Pharmaceuticals: MajorHealth Technology ProNoxis AB develops small-molecule drugs to treat chronic inflammation. The company was founded in 2009 and is headquartered in Lund, Sweden. | - |
| Mathias Svahn | M | 48 | 10 years | |
| Ulf Göran Richenberg | M | 69 |
KCIF Fund Management AB
| 13 years |
| Sofie Falk Jansson | F | 38 | 6 years | |
| Camilla Sandberg | F | 57 | 7 years | |
| Patrik Fagerholm | M | 57 | 3 years | |
| Francesca Chiodi | F | - |
IMED AB
 IMED AB Drugstore ChainsRetail Trade IMED AB is focused on the development and commercialization of fully human monoclonal antibodies for treatment of immune disorders and diseases such as ischemia/reperfusion injury, HIV and cancer. IMED’s unique antibodies modulate the natural process of cell death called apoptosis by selective and specific blocking or induction of central signaling pathways. IMED AB is a privately owned biotechnology company funded by Karolinska Development and LinkMed AB and intends to out-license its products to pharmaceutical companies. | 23 years |
| Lyda M. Osorio | M | - |
IMED AB
IMED AB Drugstore ChainsRetail Trade IMED AB is focused on the development and commercialization of fully human monoclonal antibodies for treatment of immune disorders and diseases such as ischemia/reperfusion injury, HIV and cancer. IMED’s unique antibodies modulate the natural process of cell death called apoptosis by selective and specific blocking or induction of central signaling pathways. IMED AB is a privately owned biotechnology company funded by Karolinska Development and LinkMed AB and intends to out-license its products to pharmaceutical companies. | - |
| Carl-Gustaf Johansson | M | 87 |
IMED AB
IMED AB Drugstore ChainsRetail Trade IMED AB is focused on the development and commercialization of fully human monoclonal antibodies for treatment of immune disorders and diseases such as ischemia/reperfusion injury, HIV and cancer. IMED’s unique antibodies modulate the natural process of cell death called apoptosis by selective and specific blocking or induction of central signaling pathways. IMED AB is a privately owned biotechnology company funded by Karolinska Development and LinkMed AB and intends to out-license its products to pharmaceutical companies. | - |
| Olof Ulf Stefan Björklund | M | 68 |
ProNoxis AB
ProNoxis AB Pharmaceuticals: MajorHealth Technology ProNoxis AB develops small-molecule drugs to treat chronic inflammation. The company was founded in 2009 and is headquartered in Lund, Sweden. | - |
| Magnus Doverskog | M | - |
IMED AB
IMED AB Drugstore ChainsRetail Trade IMED AB is focused on the development and commercialization of fully human monoclonal antibodies for treatment of immune disorders and diseases such as ischemia/reperfusion injury, HIV and cancer. IMED’s unique antibodies modulate the natural process of cell death called apoptosis by selective and specific blocking or induction of central signaling pathways. IMED AB is a privately owned biotechnology company funded by Karolinska Development and LinkMed AB and intends to out-license its products to pharmaceutical companies. | - |
| Eva Montgomerie | F | 66 | 17 years | |
| Ingemar Lagerlöf | M | 75 |
IMED AB
IMED AB Drugstore ChainsRetail Trade IMED AB is focused on the development and commercialization of fully human monoclonal antibodies for treatment of immune disorders and diseases such as ischemia/reperfusion injury, HIV and cancer. IMED’s unique antibodies modulate the natural process of cell death called apoptosis by selective and specific blocking or induction of central signaling pathways. IMED AB is a privately owned biotechnology company funded by Karolinska Development and LinkMed AB and intends to out-license its products to pharmaceutical companies. | 23 years |
| Johan Dighed | M | 51 |
KCIF Fund Management AB
| - |
| Lindsay Davies | M | 45 | 4 years | |
| Sofia Sisay | M | 43 | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Terje Kalland | M | 73 |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | 4 years |
| Gunnar Casserstedt | M | 74 |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | 6 years |
| Anders Essen-Möller | M | 83 | 10 years | |
| John Weiland | M | 68 |
Pharmacia AB
| - |
| Peter Sjöstrand | M | 78 |
Astra AB
 Astra AB Pharmaceuticals: MajorHealth Technology Astra AB used to manufacture and market cardiovascular preparations, local anesthetics, anti-infective agents and medical-care equipment. The firm's products were Pulmicort, Xylocaine, Marcaine, EMLA and Naropin. It had operations in Scandinavia, Europe, North & South America, Australia, New Zealand, Africa and Asia. The company was headquartered in Södertälje, Sweden. | 24 years |
| Hans Lennart Rudolf Wigzell | M | 86 | 14 years | |
| Michael Wilhelm Rosenlew | M | 65 | 2 years | |
| Daniel Bolanowski | M | 42 |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | 5 years |
| Fabian Benjamin Christoffer Nordin | M | 50 | - | |
| Ulrica Slåne Bjerke | F | 59 | 5 years | |
| Stig Lennart Hansson | M | 68 |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | 2 years |
| Pingis Berg-Hadenius | F | 46 | - | |
| Rune Fransson | M | 77 | 8 years | |
| Torbjørn Bjerke | M | 61 |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | 4 years |
| Per-Olof Edin | M | 84 | 7 years | |
| Sten Gunnar Otto Skolling | M | 63 |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | 7 years |
| Leo Groenewegen | M | - | - | |
| Ray Hill | M | 79 | - | |
| Ola Flink | M | 80 |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | 5 years |
| Stig Michael Sundström | M | 61 | 3 years | |
| Michael Owens | M | 68 | 5 years | |
| Peter Hakim Zerhouni | M | 52 | - | |
| Lars Rickard Backsell | M | 72 |
Pharmacia AB
| 4 years |
| Erik Haeffler | M | 57 |
Astra AB
Astra AB Pharmaceuticals: MajorHealth Technology Astra AB used to manufacture and market cardiovascular preparations, local anesthetics, anti-infective agents and medical-care equipment. The firm's products were Pulmicort, Xylocaine, Marcaine, EMLA and Naropin. It had operations in Scandinavia, Europe, North & South America, Australia, New Zealand, Africa and Asia. The company was headquartered in Södertälje, Sweden. | 7 years |
| Kjell Göran Stenberg | M | 72 |
Astra AB
Astra AB Pharmaceuticals: MajorHealth Technology Astra AB used to manufacture and market cardiovascular preparations, local anesthetics, anti-infective agents and medical-care equipment. The firm's products were Pulmicort, Xylocaine, Marcaine, EMLA and Naropin. It had operations in Scandinavia, Europe, North & South America, Australia, New Zealand, Africa and Asia. The company was headquartered in Södertälje, Sweden. | 25 years |
| Robin Wright | M | 59 |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | 3 years |
| Leif Niclas Fredrik Löwgren | M | 54 | - | |
| Lena Degling Wilkingsson | M | - | - | |
| Gunilla Andersson | F | 63 |
Pharmacia AB
| 6 years |
| Sofia Fredrikson | F | 41 | 3 years | |
| Marek Poszepczynski | M | - | 2 years | |
| Rolf Classon | M | 79 |
Pharmacia AB
| 5 years |
| Thomas Bengt Eldered | M | 64 |
Pharmacia AB
| 8 years |
| Ulf Ljungberg | M | - |
Astra AB
Astra AB Pharmaceuticals: MajorHealth Technology Astra AB used to manufacture and market cardiovascular preparations, local anesthetics, anti-infective agents and medical-care equipment. The firm's products were Pulmicort, Xylocaine, Marcaine, EMLA and Naropin. It had operations in Scandinavia, Europe, North & South America, Australia, New Zealand, Africa and Asia. The company was headquartered in Södertälje, Sweden. | 3 years |
| Uli Alf Hacksell | M | 74 |
Astra AB
Astra AB Pharmaceuticals: MajorHealth Technology Astra AB used to manufacture and market cardiovascular preparations, local anesthetics, anti-infective agents and medical-care equipment. The firm's products were Pulmicort, Xylocaine, Marcaine, EMLA and Naropin. It had operations in Scandinavia, Europe, North & South America, Australia, New Zealand, Africa and Asia. The company was headquartered in Södertälje, Sweden. | 8 years |
| Håkan Lars Mogren | M | 79 |
Astra AB
Astra AB Pharmaceuticals: MajorHealth Technology Astra AB used to manufacture and market cardiovascular preparations, local anesthetics, anti-infective agents and medical-care equipment. The firm's products were Pulmicort, Xylocaine, Marcaine, EMLA and Naropin. It had operations in Scandinavia, Europe, North & South America, Australia, New Zealand, Africa and Asia. The company was headquartered in Södertälje, Sweden. | 11 years |
| Sven Arne Andréasson | M | 72 |
Pharmacia AB
| 23 years |
| Erik Georg Danielsson | M | 80 |
Pharmacia AB
| 6 years |
| Robert A. Conerly | M | 65 |
Astra AB
Astra AB Pharmaceuticals: MajorHealth Technology Astra AB used to manufacture and market cardiovascular preparations, local anesthetics, anti-infective agents and medical-care equipment. The firm's products were Pulmicort, Xylocaine, Marcaine, EMLA and Naropin. It had operations in Scandinavia, Europe, North & South America, Australia, New Zealand, Africa and Asia. The company was headquartered in Södertälje, Sweden. | 1 years |
| Bo Jesper Hansen | M | 66 |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | 6 years |
| Erna Möller | F | - |
Astra AB
Astra AB Pharmaceuticals: MajorHealth Technology Astra AB used to manufacture and market cardiovascular preparations, local anesthetics, anti-infective agents and medical-care equipment. The firm's products were Pulmicort, Xylocaine, Marcaine, EMLA and Naropin. It had operations in Scandinavia, Europe, North & South America, Australia, New Zealand, Africa and Asia. The company was headquartered in Södertälje, Sweden. | - |
| Inger Birgitta Fogelberg | F | - |
Pharmacia AB
| 10 years |
| Hans Ture Staffan Ek | M | 79 |
Pharmacia AB
| 20 years |
| Jonas Frick | M | 66 |
Pharmacia AB
| - |
| Karl Härfstrand | M | 66 |
Pharmacia AB
| 15 years |
| Wenche Nelly A. Rolfsen Sandsborg | M | 72 |
Pharmacia AB
| 16 years |
| Conny Börje Bogentoft | M | 81 |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | 7 years |
| Annika Margareta Grahn-Westin | F | - |
Pharmacia AB
| 19 years |
| Sven Håkan Björklund | M | 68 |
Astra AB
Astra AB Pharmaceuticals: MajorHealth Technology Astra AB used to manufacture and market cardiovascular preparations, local anesthetics, anti-infective agents and medical-care equipment. The firm's products were Pulmicort, Xylocaine, Marcaine, EMLA and Naropin. It had operations in Scandinavia, Europe, North & South America, Australia, New Zealand, Africa and Asia. The company was headquartered in Södertälje, Sweden. | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Sweden | 67 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Hans-Peter Torsten Ekre
- Personal Network
